Susquehanna International Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-62,800
Closed -$2.37M 13719
2021
Q1
$2.37M Buy
62,800
+35,800
+133% +$893K ﹤0.01% 5512
2020
Q4
$459K Buy
27,000
+13,800
+105% +$173K ﹤0.01% 8480
2020
Q3
$62K Buy
+13,200
New +$67K ﹤0.01% 10143
2020
Q2
Sell
-10,800
Closed -$25K 11342
2020
Q1
$25K Buy
+10,800
New +$45.8K ﹤0.01% 9891
2019
Q2
Sell
-26,000
Closed -$348K 11113
2019
Q1
$348K Buy
26,000
+14,300
+122% +$163K ﹤0.01% 6959
2018
Q4
$109K Sell
11,700
-75,100
-87% -$894K ﹤0.01% 8176
2018
Q3
$1.21M Buy
86,800
+55,800
+180% +$830K ﹤0.01% 4864
2018
Q2
$490K Buy
+31,000
New +$541K ﹤0.01% 6828
2018
Q1
Sell
-37,500
Closed -$822K 10548
2017
Q4
$822K Sell
37,500
-28,500
-43% -$917K ﹤0.01% 5632
2017
Q3
$2.7M Buy
66,000
+53,900
+445% +$1.69M ﹤0.01% 3391
2017
Q2
$364K Sell
12,100
-10,900
-47% -$340K ﹤0.01% 7227
2017
Q1
$831K Buy
23,000
+7,500
+48% +$331K ﹤0.01% 5526
2016
Q4
$777K Buy
15,500
+8,300
+115% +$436K ﹤0.01% 6051
2016
Q3
$378K Sell
7,200
-2,500
-26% -$119K ﹤0.01% 6557
2016
Q2
$401K Sell
9,700
-3,400
-26% -$148K ﹤0.01% 6491
2016
Q1
$532K Sell
13,100
-23,200
-64% -$797K ﹤0.01% 6292
2015
Q4
$1.51M Buy
+36,300
New +$1.22M ﹤0.01% 4613

Susquehanna International Group's FPRX Position: Q2 2021 in Review

Susquehanna International Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 29,986 shares — an estimated $1.13M sold.

Susquehanna International Group first reported a position in FPRX in Q1 2015 and held it in 10 quarters. The position peaked at $1.13M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Susquehanna International Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Susquehanna International Group sold 29,986 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $1.13M.
  • Susquehanna International Group first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 10 quarters.
  • Susquehanna International Group's Five Prime Therapeutics, Inc. position peaked at $1.13M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Susquehanna International Group's 13F filing for Q2 2021, filed 11 Aug 2021.